MedPath

BAYER AG

BAYER AG logo
🇩🇪Germany
Ownership
Public
Established
1863-08-01
Employees
99.7K
Market Cap
$30.1B
Website
http://www.bayer.com
biospace.com
·

Bayer and MOMA Therapeutics Enter Collaboration and License Agreement in Oncology

Bayer and MOMA Therapeutics collaborate to develop a small molecule oncology program using MOMA’s KNOMATIC™ platform, with Bayer responsible for preclinical, development, and commercial activities. MOMA receives upfront payment, collaboration fee, and potential milestones and royalties.
globenewswire.com
·

OTC Drug and Dietary Supplement Market Opportunities and

The global OTC drug and dietary supplement market was valued at $310.96 billion in 2023, expected to reach $438.25 billion by 2028, and $632.1 billion by 2033. Factors driving growth include health consciousness, dietary supplement demand, government initiatives, aging population, and e-commerce expansion. Key segments include vitamin and dietary supplements, tablets, and pharmacies. North America leads the market, with Asia-Pacific and Africa expected to grow fastest.
barchart.com
·

Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi And Bayer

Switch Market flag for country-specific data. Right-click for chart options. Use arrows to navigate symbols.
finance.yahoo.com
·

5 Large Drug Stocks to Watch From a Thriving Industry

The drug and biotech industry thrives on M&A, new drug launches, and pipeline successes, with obesity drugs from Novo Nordisk and Eli Lilly leading. Large drugmakers like Eli Lilly, AstraZeneca, Pfizer, Sanofi, and Bayer are profitable and innovative, focusing on areas like weight loss, inflammation, and Alzheimer’s. Despite headwinds such as pipeline setbacks and macroeconomic uncertainty, investment in drug/biotech stocks has surged. The Zacks Large Cap Pharmaceuticals industry ranks in the top 19% of Zacks industries, outperforming the Zacks Medical Sector but slightly underperforming the S&P 500.
openpr.com
·

New Innovations in Personalized Medicine Market Technology

The report on the Personalized Medicine Market by Vantage Market Research highlights market size, forecast, opportunities, key drivers, regulatory scenario, industry trends, new product approvals, competitive landscape, and regional analysis. Key players include Abbott Laboratories, Merck & Co., AstraZeneca, Pfizer, GlaxoSmithKline, Novartis, Amgen, Bayer, Eli Lilly, Illumina, Danaher, QIAGEN, 23andMe, Roche, Thermo Fisher Scientific, GE Healthcare, and Precision Biologics. Market types cover diagnostics, therapeutics, medical care, and nutrition, while applications include oncology, neurology, cardiology, antiviral, psychiatry, immunology, and others. The report also examines COVID-19's impact on the market.
theglobeandmail.com
·

1 AI Biotech Stock That Just Scored a Major Milestone

AI-powered Recursion Pharmaceuticals (RXRX) hit a milestone with FDA approval for REC-1245, targeting RBM39 in advanced cancers. The company plans to merge with Exscientia (EXAI) in 2025 and has partnerships with Bayer (BAYZF) and Sanofi (SNY), with an average 12-month target price of $10.14 for RXRX stock.
en.sggp.org.vn
·

Application of agricultural biotechnology in Vietnam faces future challenges

Vietnam faces challenges in biotechnology development despite global agricultural successes, with limited R&D investment and policy barriers like Decree 70 hindering progress. The Ministry of Agriculture and Rural Development aims to prioritize key laboratories for cellular, nano, and gene editing technologies to enhance competitiveness across sectors.
theglobeandmail.com
·

Should You Buy the Dip on This Top Growth Stock?

Regeneron Pharmaceuticals faces headwinds with Eylea, its key eye disease treatment, due to biosimilar competition and a recent court decision favoring Amgen. Despite this, Regeneron's higher-dose Eylea and growth driver Dupixent, an eczema treatment, suggest resilience. Long-term biotech investors are advised to consider buying Regeneron shares on the dip.
© Copyright 2025. All Rights Reserved by MedPath